Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Breast Cancer

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 82 articles:
HTML format



Single Articles


    June 2022
  1. DING K, Chen F, Priedigkeit N, Brown DD, et al
    Single cell heterogeneity and evolution of breast cancer bone metastasis and organoids reveals therapeutic targets for precision medicine.
    Ann Oncol. 2022 Jun 25. pii: S0923-7534(22)01734.
    PubMed    


    May 2022
  2. VAN BAELEN K, Geukens T, Maetens M, Tjan-Heijnen V, et al
    Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.
    Ann Oncol. 2022 May 20. pii: S0923-7534(22)01167.
    PubMed     Abstract available


  3. LOIBL S, Untch M, Burchardi N, Huober J, et al
    Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Onco
    Ann Oncol. 2022 May 17. pii: S0923-7534(22)00676.
    PubMed    


  4. MARCZYK M, Mrukwa A, Yau C, Wolf D, et al
    Treatment Efficacy Score - continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.
    Ann Oncol. 2022 May 2. pii: S0923-7534(22)00762.
    PubMed     Abstract available


    April 2022
  5. TARANTINO P, Jin Q, Mittendorf EA, King TA, et al
    Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib.
    Ann Oncol. 2022 Apr 28. pii: S0923-7534(22)00754.
    PubMed    


  6. PICCART MJ, Kalinsky K, Gray R, Barlow WE, et al
    Erratum to "Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust": [Annals of Oncology 32 (2021) 1077-1082].
    Ann Oncol. 2022 Apr 26. pii: S0923-7534(22)00673.
    PubMed    


  7. GEYER CE, Sikov WM, Loibl S
    Reply to the Letter to the Editor "Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple negative breast cancer" by A. Okines and N. Turner.
    Ann Oncol. 2022 Apr 4. pii: S0923-7534(22)00671.
    PubMed    


    March 2022
  8. RUGO HS, O'Shaughnessy J, Boyle F, Toi M, et al
    Adjuvant Abemaciclib Combined with Endocrine Therapy for High Risk Early Breast Cancer: Safety and Patient-Reported Outcomes From the monarchE Study.
    Ann Oncol. 2022 Mar 22. pii: S0923-7534(22)00383.
    PubMed     Abstract available


  9. TOMASIK B, Bienkowski M, Jassem J
    Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the die has not been cast.
    Ann Oncol. 2022 Mar 16. pii: S0923-7534(22)00384.
    PubMed    


  10. FLEMING GF, Pagani O, Regan MM, Walley BA, et al
    Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
    Ann Oncol. 2022 Mar 14. pii: S0923-7534(22)00380.
    PubMed    


  11. OKINES A, Turner N
    Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple negative breast cancer.
    Ann Oncol. 2022 Mar 14. pii: S0923-7534(22)00364.
    PubMed    


  12. ZANELLI S, Fiorio E, Zampiva I, Zacchi F, et al
    Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona.
    Ann Oncol. 2022 Mar 8. pii: S0923-7534(22)00363.
    PubMed    


    February 2022
  13. GIANNI L, Huang CS, Egle D, Bermejo B, et al
    Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study.
    Ann Oncol. 2022 Feb 16. pii: S0923-7534(22)00113.
    PubMed     Abstract available


    January 2022
  14. GEYER CE JR, Sikov WM, Huober J, Rugo HS, et al
    Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial.
    Ann Oncol. 2022 Jan 27. pii: S0923-7534(22)00018.
    PubMed     Abstract available


  15. DALMARTELLO M, La Vecchia C, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2022 with focus on ovarian cancer.
    Ann Oncol. 2022 Jan 13. pii: S0923-7534(21)04881.
    PubMed     Abstract available


  16. GAO JJ, Krol D, Narayan P, Cardoso F, et al
    Corrigendum to "Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria": [Annals of Oncology 32 (2021) 950-953].
    Ann Oncol. 2022 Jan 7. pii: S0923-7534(22)00002.
    PubMed    


  17. NITZ UA, Gluz O, Christgen M, Grischke EM, et al
    Corrigendum to "De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertu
    Ann Oncol. 2022 Jan 7. pii: S0923-7534(21)04883.
    PubMed    


    December 2021
  18. CURIGLIANO G, Mueller V, Borges V, Hamilton E, et al
    Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis.
    Ann Oncol. 2021 Dec 22. pii: S0923-7534(21)04879.
    PubMed     Abstract available


  19. TARANTINO P, Burstein HJ, Lin NU, Krop IE, et al
    Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
    Ann Oncol. 2021 Dec 20. pii: S0923-7534(21)04877.
    PubMed    


  20. SPRING L, Matikas A, Bardia A, Foukakis T, et al
    Adjuvant abemaciclib for high-risk breast cancer: the story continues.
    Ann Oncol. 2021;32:1457-1459.
    PubMed    


    November 2021
  21. CARDOZO JMNL, Byng D, Drukker CA, Schmidt MK, et al
    Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial.
    Ann Oncol. 2021 Nov 30. pii: S0923-7534(21)04829.
    PubMed     Abstract available


  22. POGGIO F, Tagliamento M, Ceppi M, Bruzzone M, et al
    Adding a platinum agent to neoadjuvant chemotherapy for triple negative breast cancer: the end of the debate.
    Ann Oncol. 2021 Nov 30. pii: S0923-7534(21)04831.
    PubMed    


  23. HAN HS, Arun BK, Kaufman B, Wildiers H, et al
    Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial.
    Ann Oncol. 2021 Nov 30. pii: S0923-7534(21)04833.
    PubMed     Abstract available


  24. EMENS LA, Adams S, Barrios CH, Dieras V, et al
    Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993.
    Ann Oncol. 2021 Nov 2. pii: S0923-7534(21)04520.
    PubMed    


    October 2021
  25. HARBECK N, Rastogi P, Shahir A, Johnston S, et al
    Letter to the Editor for "Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study".
    Ann Oncol. 2021 Oct 28. pii: S0923-7534(21)04551.
    PubMed    


  26. FUENTES-ANTRAS J, Cescon DW
    PARP inhibitor sensitivity in BRCA-related metastatic breast cancer: an OlympiAD later.
    Ann Oncol. 2021 Oct 19. pii: S0923-7534(21)04523.
    PubMed    


  27. GENNARI A, Andre F, Barrios CH, Cortes J, et al
    ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.
    Ann Oncol. 2021 Oct 13. pii: S0923-7534(21)04498.
    PubMed    


  28. HE W, Eriksson M, Eliasson E, Grassmann F, et al
    CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.
    Ann Oncol. 2021;32:1286-1293.
    PubMed     Abstract available


    September 2021
  29. HARBECK N, Rastogi P, Martin M, Tolaney SM, et al
    Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study.
    Ann Oncol. 2021 Sep 29. pii: S0923-7534(21)04494.
    PubMed     Abstract available


  30. WANG Y, Acs B, Robertson S, Liu B, et al
    Improved breast cancer histological grading using deep learning.
    Ann Oncol. 2021 Sep 29. pii: S0923-7534(21)04486.
    PubMed     Abstract available


  31. LLOP-GUEVARA A, Loibl S, Villacampa G, Vladimirova V, et al
    Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
    Ann Oncol. 2021 Sep 11. pii: S0923-7534(21)04478.
    PubMed     Abstract available


  32. HODGSON D, Lai Z, Dearden S, Barrett JC, et al
    Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
    Ann Oncol. 2021 Sep 6. pii: S0923-7534(21)04458.
    PubMed     Abstract available


    August 2021
  33. SALGADO R, Peg V, Ruschoff J, Vincent-Salomon A, et al
    Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: the pathologists' perspective.
    Ann Oncol. 2021 Aug 27. pii: S0923-7534(21)04278.
    PubMed    


  34. SCHRODI S, Braun M, Andrulat A, Harbeck N, et al
    Outcome of breast cancer patients with low hormone receptor positivity: Analysis of a 15-year population-based cohort.
    Ann Oncol. 2021 Aug 19. pii: S0923-7534(21)04218.
    PubMed     Abstract available


  35. SLAMON DJ, Neven P, Chia S, Jerusalem G, et al
    Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [An
    Ann Oncol. 2021 Aug 16. pii: S0923-7534(21)02209.
    PubMed    


  36. RASSY E, Pistilli B
    Are all taxanes equal in patients with HER2-positive breast cancer? PERUSing the safety and efficacy of trastuzumab plus pertuzumab and taxanes in real-life usual care.
    Ann Oncol. 2021 Aug 14. pii: S0923-7534(21)03980.
    PubMed    


  37. JERUSALEM G, Farah S, Courtois A, Chirgwin J, et al
    Continuous vs intermittent extended adjuvant letrozole for breast cancer: Final results of randomized phase 3 SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.
    Ann Oncol. 2021 Aug 9. pii: S0923-7534(21)02492.
    PubMed     Abstract available


  38. EMENS LA, Adams S, Barrios CH, Dieras V, et al
    Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; volume 32: 983-993.
    Ann Oncol. 2021 Aug 2. pii: S0923-7534(21)02211.
    PubMed    


  39. EMENS LA, Adams S, Barrios CH, Dieras V, et al
    First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.
    Ann Oncol. 2021;32:983-993.
    PubMed     Abstract available


  40. VOORWERK L, Kok M
    'IMpassionate conflicts' in immunotherapy trials for metastatic triple-negative breast cancer.
    Ann Oncol. 2021;32:947-949.
    PubMed    


  41. PAGE K, Martinson LJ, Hastings RK, Fernandez-Garcia D, et al
    Prevalence of ctDNA in early screen-detected breast cancers using highly sensitive and specific dual molecular barcoded personalised mutation assays.
    Ann Oncol. 2021;32:1057-1060.
    PubMed    


    July 2021
  42. LOI S, Michiels S, Adams S, Loibl S, et al
    The journey of tumor infiltrating lymphocytes (TIL) as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition.
    Ann Oncol. 2021 Jul 23. pii: S0923-7534(21)02185.
    PubMed     Abstract available


  43. BURSTEIN HJ, Curigliano G, Thurlimann B, Weber WP, et al
    CUSTOMIZING LOCAL AND SYSTEMIC THERAPIES FOR WOMEN WITH EARLY BREAST CANCER: The St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.
    Ann Oncol. 2021 Jul 6. pii: S0923-7534(21)02104.
    PubMed     Abstract available


  44. MILES D, Ciruelos E, Schneeweiss A, Puglisi F, et al
    Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
    Ann Oncol. 2021 Jul 2. pii: S0923-7534(21)02105.
    PubMed     Abstract available


  45. MILES D, Gligorov J, Andre F, Cameron D, et al
    Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
    Ann Oncol. 2021 Jul 1. pii: S0923-7534(21)02026.
    PubMed     Abstract available


    June 2021
  46. BARDIA A, Tolaney SM, Punie K, Loirat D, et al
    Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.
    Ann Oncol. 2021 Jun 8. pii: S0923-7534(21)02047.
    PubMed     Abstract available


    May 2021
  47. PICCART MJ, Kalinsky K, Gray R, Barlow WE, et al
    Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust.
    Ann Oncol. 2021 May 31. pii: S0923-7534(21)02029.
    PubMed    


  48. MAMOUNAS EP
    Characteristics of residual invasive breast cancer after neoadjuvant therapy in the KATHERINE study.
    Ann Oncol. 2021 May 28. pii: S0923-7534(21)02027.
    PubMed    


  49. SLAMON DJ, Neven P, Chia S, Jerusalem G, et al
    Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase 3 randomized MONALEESA-3 trial: updated overall survival.
    Ann Oncol. 2021 May 15. pii: S0923-7534(21)01553.
    PubMed     Abstract available


  50. GAO JJ, Krol D, Narayan P, Cardoso F, et al
    Bringing Safe and Effective Therapies to Premenopausal Women with Breast Cancer: Efforts to Broaden Eligibility Criteria.
    Ann Oncol. 2021 May 12. pii: S0923-7534(21)01556.
    PubMed    


    April 2021
  51. MAMOUNAS EP, Untch M, Mano MS, Huang CS, et al
    Adjuvant T-DM1 versus Trastuzumab in Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer: Subgroup Analyses from KATHERINE.
    Ann Oncol. 2021 Apr 28. pii: S0923-7534(21)01168.
    PubMed     Abstract available


    February 2021
  52. DU L, Yau C, Brown-Swigart L, Gould R, et al
    Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer prior to chemo-endocrine therapy.
    Ann Oncol. 2021 Feb 19. pii: S0923-7534(21)00128.
    PubMed     Abstract available


  53. AGOSTINETTO E, Ignatiadis M
    Optimal treatment for aromatase inhibitor-resistant metastatic breast cancer patients: Lessons from the PEARL study.
    Ann Oncol. 2021 Feb 8. pii: S0923-7534(21)00106.
    PubMed    


  54. BRUFSKY A, Kim SB, Zvirbule Z, Eniu A, et al
    A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis.
    Ann Oncol. 2021 Feb 1. pii: S0923-7534(21)00093.
    PubMed     Abstract available


  55. MATIKAS A, Foukakis T
    SOLAR1s: alpelisib returns to earth?
    Ann Oncol. 2021;32:129-132.
    PubMed    


  56. VANACKER H, Cassier PA, Bachelot T
    The complex balance of PI3K inhibition.
    Ann Oncol. 2021;32:127-128.
    PubMed    


    January 2021
  57. MONTOPOLI M, Zorzi M, Cocetta V, Prayer-Galetti T, et al
    Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy.
    Ann Oncol. 2021 Jan 29. pii: S0923-7534(21)00097.
    PubMed    


  58. CARIOLI G, Malvezzi M, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer.
    Ann Oncol. 2021 Jan 21. pii: S0923-7534(21)00014.
    PubMed     Abstract available


  59. DENKERT C, Untch M, Benz S, Schneeweiss A, et al
    Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy.
    Ann Oncol. 2021 Jan 5. pii: S0923-7534(20)43224.
    PubMed     Abstract available


    December 2020
  60. LOHMANN AE, Goodwin PJ
    Diabetes, metformin and breast cancer: a tangled web.
    Ann Oncol. 2020 Dec 31. pii: S0923-7534(20)43222.
    PubMed    


  61. MARTIN M, Zielinski C, Ruiz-Borrego M, Carrasco E, et al
    Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.
    Ann Oncol. 2020 Dec 29. pii: S0923-7534(20)43221.
    PubMed     Abstract available


  62. PARK YM, Bookwalter DB, O'Brien KM, Jackson CL, et al
    A Prospective Study of Type 2 diabetes, metformin use, and risk of breast cancer.
    Ann Oncol. 2020 Dec 19. pii: S0923-7534(20)43214.
    PubMed     Abstract available


  63. FRANZOI MA, Romano E, Piccart M
    Immunotherapy for early breast cancer: too soon, too superficial, or just right?
    Ann Oncol. 2020 Dec 8. pii: S0923-7534(20)43198.
    PubMed     Abstract available


  64. GRINSHPUN A, Moss J, Uziely B
    Key Role for Liquid Biopsy in the Elimination of Breast Cancer Surgery following Neoadjuvant Therapy.
    Ann Oncol. 2020 Dec 7. pii: S0923-7534(20)43201.
    PubMed    


  65. AMIRI-KORDESTANI L, Xie D, Tolaney SM, Bloomquist E, et al
    A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials.
    Ann Oncol. 2020;31:1704-1708.
    PubMed     Abstract available


    November 2020
  66. ANDRE F, Ciruelos EM, Juric D, Loibl S, et al
    Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1.
    Ann Oncol. 2020 Nov 24. pii: S0923-7534(20)43166.
    PubMed     Abstract available


  67. EIKESDAL HP, Yndestad S, Elzawahry A, Llop-Guevara A, et al
    Olaparib Monotherapy as Primary Treatment in Unselected Triple Negative Breast Cancer.
    Ann Oncol. 2020 Nov 23. pii: S0923-7534(20)43164.
    PubMed     Abstract available


  68. MAGBANUA MJM, Swigart LB, Wu HT, Hirst GL, et al
    Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
    Ann Oncol. 2020 Nov 21. pii: S0923-7534(20)43162.
    PubMed     Abstract available


  69. XU B, Sun T, Zhang Q, Zhang P, et al
    Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase 3 randomised controlled trial.
    Ann Oncol. 2020 Nov 11. pii: S0923-7534(20)43130.
    PubMed     Abstract available


  70. DENT S, Cortes J, Im YH, Dieras V, et al
    Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
    Ann Oncol. 2020 Nov 10. pii: S0923-7534(20)43124.
    PubMed     Abstract available


  71. PUSZTAI L
    PARP inhibition in homologous recombination deficient early stage breast cancer.
    Ann Oncol. 2020 Nov 9. pii: S0923-7534(20)43128.
    PubMed    


    October 2020
  72. FASCHING PA, Link T, Hauke J, Seither F, et al
    Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
    Ann Oncol. 2020 Oct 21. pii: S0923-7534(20)42963.
    PubMed     Abstract available


  73. SIPOS O, Tovey H, Quist J, Haider S, et al
    Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in Triple Negative Breast Cancer: the TNT trial.
    Ann Oncol. 2020 Oct 21. pii: S0923-7534(20)42977.
    PubMed     Abstract available


  74. STECKLEIN SR, Sharma P
    Last but not Least: Antibody-Drug Conjugates in Hormone Receptor-Positive Metastatic Breast Cancer.
    Ann Oncol. 2020 Oct 7. pii: S0923-7534(20)42492.
    PubMed    


  75. LIN NU
    Reevaluating the role of antibody-drug conjugates in the treatment of patients with brain metastases.
    Ann Oncol. 2020;31:1279-1281.
    PubMed    


    September 2020
  76. GRINDA T, Delaloge S
    Survival benefits of PARP inhibitors in advanced breast cancer: a mirage?
    Ann Oncol. 2020 Sep 29. pii: S0923-7534(20)42468.
    PubMed    


  77. CARDOSO F, Paluch-Shimon S, Senkus E, Curigliano G, et al
    5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)(dagger).
    Ann Oncol. 2020 Sep 23. pii: S0923-7534(20)42460.
    PubMed    


  78. KALINSKY K, Diamond JR, Vahdat LT, Tolaney SM, et al
    Sacituzumab Govitecan in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Final Results from a Phase 1/2, Single-Arm, Basket Trial.
    Ann Oncol. 2020 Sep 15. pii: S0923-7534(20)42445.
    PubMed     Abstract available


  79. KARN T, Denkert C, Weber KE, Holtrich U, et al
    Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.
    Ann Oncol. 2020;31:1216-1222.
    PubMed     Abstract available


    May 2020
  80. CARIOLI G, Bertuccio P, Boffetta P, Levi F, et al
    European cancer mortality predictions for the year 2020 with a focus on prostate cancer.
    Ann Oncol. 2020;31:650-658.
    PubMed     Abstract available


    March 2020
  81. YVER A, Agatsuma T, Soria JC
    The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers.
    Ann Oncol. 2020;31:430-434.
    PubMed    


  82. KURZROCK R, Bowles DW, Kang H, Meric-Bernstam F, et al
    Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.
    Ann Oncol. 2020;31:412-421.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: